<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1529">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04657497</url>
  </required_header>
  <id_info>
    <org_study_id>FOY305-01</org_study_id>
    <nct_id>NCT04657497</nct_id>
  </id_info>
  <brief_title>A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)</brief_title>
  <official_title>A Placebo-controlled, Multicenter, Double-blind, Randomized, Parallel-group Comparative Study in SARS-CoV-2 Infection (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy and safety of FOY-305 in patients with SARS-CoV-2 infection (COVID-19)&#xD;
      in a placebo-controlled, multicenter, double-blind, randomized, parallel-group comparative&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to SARS-CoV-2 negative test</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Time to SARS-CoV-2 negative test as assessed by the local laboratory</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to SARS-CoV-2 negative test</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Time to SARS-CoV-2 negative test as assessed by the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who test negative for SARS-CoV-2</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Proportion of subjects who test negative for SARS-CoV-2 (as assessed by the local and central laboratories)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ordinal scale for severity</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Ordinal scale for severity. The minimum score is 0: No clinical or virological evidence of infection, representing the better outcome, and the maximum value is 8: Death, representing the worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects on mechanical ventilator</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Proportion of subjects on mechanical ventilator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival status (alive/death)</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Proportion of subjects alive or death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>SARS-CoV-2 Infection (COVID-19)</condition>
  <arm_group>
    <arm_group_label>FOY-305 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Camostat Mesilate tablets 600 mg will be orally administered 4 times daily, before breakfast, before lunch, before evening meal, and at bedtime. The treatment period is up to 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets will be orally administered 4 times daily, before breakfast, before lunch, before evening meal, and at bedtime. The treatment period is up to 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOY-305</intervention_name>
    <description>Specified Dosage and Duration of Treatment</description>
    <arm_group_label>FOY-305 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Specified Dosage and Duration of Treatment</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Inpatient or outpatient: Inpatient&#xD;
&#xD;
          2. Positive SARS-CoV-2 test by a method eligible for definitive diagnosis&#xD;
&#xD;
          3. Enrollment in this study within 5 days after onset of symptoms of SARS-CoV-2 infection&#xD;
             (COVID-19) (for asymptomatic patients, enrollment in this study within 5 days after&#xD;
             collection of the sample that tested positive)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Receiving oxygen therapy&#xD;
&#xD;
          2. Difficulty in swallowing oral medication&#xD;
&#xD;
          3. History of COVID-19&#xD;
&#xD;
          4. History of vaccination against COVID-19&#xD;
&#xD;
          5. Taking camostat mesilate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naoyuki Komura</last_name>
    <role>Study Director</role>
    <affiliation>Ono Pharmaceutical Co. Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ono Pharmaceutical Co. Ltd Medicine counseling department</last_name>
    <email>clinical_trial@ono.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chiba Clinical Site 1</name>
      <address>
        <city>Narita</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fukuoka Clinical Site 1</name>
      <address>
        <city>Okawa</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ishikawa Clinical Site 1</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanagawa Clinical Site 1</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanagawa Clinical Site 2</name>
      <address>
        <city>Yokosuka</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mie Clinical Site 1</name>
      <address>
        <city>Yokkaichi</city>
        <state>Mie</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saitama Clinical Site 1</name>
      <address>
        <city>Kuki</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saitama Clinical Site 2</name>
      <address>
        <city>Kumagaya</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical Site 5</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical Site 9</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical Site1</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical Site 7</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical Site 3</name>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical Site 4</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical Site 8</name>
      <address>
        <city>Sibuya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical Site2</name>
      <address>
        <city>Sibuya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical Site 6</name>
      <address>
        <city>Tachikawa</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka Clinical Site 1</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Camostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_url>https://www.ono.co.jp/eng/rd/policy.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

